Skip to content

Safety and efficacy of Aromatase inhibitor for fertility treatment of young breast cancer patients.

Safety and efficacy of Aromatase inhibitor for fertility treatment of young breast cancer patients. - Effect of aromatase inhibitor for fertility treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031180419
Enrollment
300
Registered
2019-03-22
Start date
2015-01-23
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Start takig orally of letrozole (e.x. FEMARA 2.5mg, 1 to 2 tablet/day) on the assigned day, and stop taking FEMARA after the confirmation that the concentration of estradiol is less than 50pg/ml.

Sponsors

Suzuki Nao
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1, Diagnosed as Breast cancer with cytological or histological study 2, There is consult by letter from medical doctor who follow up the patient 3, Age 18 to 45 years-old 4, Expectable long-survival case 5, Written informed consent

Exclusion criteria

Exclusion criteria: 1, After bilateral ovariectomy 2, The patients have past-history of ovarian cancer or cervical cancer(adenocarcinoma). If there are possibilities to get worse do to fertility treatment. 3, Pregnant women 4, During lactation 5, There are severe complications (e.g. uncontrollable DM, Auto immune disease which cause thrombosis easily, past history of thrombosis) 6, AST or ALT > 100U 7, BUN > 25mg/dl, or Cre > 2.0 mg/dl 8, The patients who are determined as ineligible cases

Design outcomes

Primary

MeasureTime frame
Rate of recurrence, Birth abnormality.

Secondary

MeasureTime frame
Number of extracted oocyte, fertilization rate, birth rate.

Contacts

Public ContactSeido Takae

St. Marianna University School of Medicine

s2takae@marianna-u.ac.jp+81-44-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026